/
ALT
$2.94+$0.12 (+4.26%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$548.4M
194M shares
52-week range
$2.56 – $6.44
10% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.26%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-6.91
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.3M | $5.8M | $8.2M | $4.4M | −$68.0K | $426.0K | $20.0K | $41.0K |
| Cost of revenue | $18.5M | $0 | $33.5M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$8.1M | $5.8M | −$25.3M | $4.4M | −$68.0K | $426.0K | $20.0K | $41.0K |
| Gross margin | -78.7% | 100.0% | -309.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $18.5M | $17.8M | $49.8M | $74.5M | $70.5M | $65.8M | $82.2M | $66.4M |
| Operating income | −$42.8M | −$21.5M | −$54.8M | −$96.9M | −$87.7M | −$95.9M | −$103.2M | −$94.5M |
| EBITDA | −$44.7M | −$20.2M | −$38.1M | −$96.5M | −$84.4M | −$87.9M | −$94.8M | −$87.0M |
| Net income | −$39.2M | −$20.5M | −$49.0M | −$97.1M | −$84.7M | −$88.4M | −$95.1M | −$88.1M |
| Net margin | -379.2% | -353.7% | -599.2% | -2201.6% | 124577.9% | -20762.2% | -475295.0% | -214861.0% |
| EPS (diluted) | -13.98 | -1.56 | -1.91 | -2.35 | -1.81 | -1.66 | -1.34 | -1.00 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6222 | $-0.68 | $-0.89–$-0.51 | 7 |
| 2027 | $26M | $-0.75 | $-1.29–$-0.46 | 7 |
| 2028 | $94M | $-0.89 | $-1.26–$-0.43 | 6 |
| 2029 | $51M | $-0.77 | $-0.77–$-0.77 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.08
Price
$2.94
Implied downside
-97%
Peer comparison
Altimmune, Inc. Common Stock
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
www.altimmune.com- Employees
- 57
- IPO / List date
- Oct 6, 2005
- HQ
- GAITHERSBURG, MD
Held by traders on TradeandTell
No one on the platform currently holds ALT.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ALT as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2018-09-14 | 1-for-30reverse |
| 2017-05-04 | 1-for-10reverse |
| 2007-07-25 | 1-for-50reverse |
Recent trades on TradeandTell
No one on the platform has traded ALT yet.
